Intervention

abiraterone acetate

ClinicalTrials.gov intervention label

Clinical trials22

Recruiting3

Common conditions17

Lead sponsors shown15

Clinical trials

22 shown

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerNCT07198633 · 2025-11-05

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154 · 2025-08-19

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossNCT05593497 · 2024-05-31

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate CancerNCT07104110 · 2025-10-01

NOT_YET_RECRUITING

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsNCT05457257 · 2022-07-29

ACTIVE_NOT_RECRUITING

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)NCT05171816 · 2021-06-24

ACTIVE_NOT_RECRUITING

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerNCT03732820 · 2018-10-31

ACTIVE_NOT_RECRUITING

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)NCT02987543 · 2017-02-06

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyNCT02960022 · 2016-12-22

ACTIVE_NOT_RECRUITING

Abiraterone-Rechallenge Study for CRPC PatientsNCT02656615 · 2016-01-01

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted AgentNCT02485691 · 2015-11-09

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate CancerNCT02025010 · 2014-01-27

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerNCT01957436 · 2013-11-13

ACTIVE_NOT_RECRUITING

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate CancerNCT01913015 · 2013-07-01

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone AcetateNCT01685268 · 2012-09-01

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate CancerNCT01685125 · 2012-09-01

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsNCT01650194 · 2012-07-09

Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate CancerNCT01543776 · 2012-01-01

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerNCT01487863 · 2011-12-01

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone TherapyNCT01309672 · 2011-08-09

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate CancerNCT01023061 · 2010-03-01

Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast CancerNCT00755885 · 2008-10-01

Common conditions

Metastatic Castration-resistant Prostate Cancer6 Prostate Cancer5 Stage IV Prostate Cancer4 Castration-resistant Prostate Cancer3 Adenocarcinoma of the Prostate2 Hormone-resistant Prostate Cancer2 Prostate Cancer Metastatic2 Recurrent Prostate Cancer2 Advanced Prostate Cancer1 Breast Cancer1 High-Risk Prostate Cancer1 Hormone Refractory Prostate Cancer1 Metastatic Hormone Sensitive Prostate Cancer1 Metastatic Prostate Cancer1 Prostatic Neoplasms1 Stage II Prostate Cancer1 Stage III Prostate Cancer1

Leading sponsors

AstraZeneca4 Astellas Pharma Global Development, Inc.3 Qilu Pharmaceutical Co., Ltd.2 Astex Pharmaceuticals, Inc.1 Aurelius Omlin1 Cancer Research UK1 Dana-Farber Cancer Institute1 Dendreon1 OHSU Knight Cancer Institute1 Sanofi1 SWOG Cancer Research Network1 UNICANCER1 University of Chicago1 University of Southern California1 University of Washington1

Trial status mix

COMPLETED10

ACTIVE_NOT_RECRUITING5

RECRUITING3

TERMINATED2

NOT_YET_RECRUITING1

UNKNOWN1

Phase mix

PHASE215

PHASE15

PHASE34

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.